You are here
CERID Bibliography
Export 75 results:
Author Title Type [ Year] Filters: Author is Buckner, Frederick S [Clear All Filters]
Cloning, heterologous expression, and substrate specificities of protein farnesyltransferases from Trypanosoma cruzi and Leishmania major. Mol Biochem Parasitol. 2002 ;122(2):181-8.
. Isothiazole dioxides: synthesis and inhibition of Trypanosoma brucei protein farnesyltransferase. Bioorg Med Chem Lett. 2002 ;12(16):2217-20.
. Leishmania major activates IL-1 alpha expression in macrophages through a MyD88-dependent pathway. Microbes Infect. 2002 ;4(8):763-71.
. Trypanosoma brucei prenylated-protein carboxyl methyltransferase prefers farnesylated substrates. Biochem J. 2002 ;367(Pt 3):809-16.
. Cloning and analysis of Trypanosoma cruzi lanosterol 14alpha-demethylase. Mol Biochem Parasitol. 2003 ;132(2):75-81.
. Oxidosqualene cyclase inhibitors as antimicrobial agents. J Med Chem. 2003 ;46(20):4240-3.
Protein farnesyl and N-myristoyl transferases: piggy-back medicinal chemistry targets for the development of antitrypanosomatid and antimalarial therapeutics. Mol Biochem Parasitol. 2003 ;126(2):155-63.
. Design and synthesis of peptidomimetic protein farnesyltransferase inhibitors as anti-Trypanosoma brucei agents. J Med Chem. 2004 ;47(2):432-45.
In vitro and in vivo antimalarial activity of peptidomimetic protein farnesyltransferase inhibitors with improved membrane permeability. Bioorg Med Chem. 2004 ;12(24):6517-26.
Colorimetric assay for screening compounds against Leishmania amastigotes grown in macrophages. Am J Trop Med Hyg. 2005 ;72(5):600-5.
. Differential drug binding by the highly conserved Plasmodium falciparum thymidylate synthase. Mol Biochem Parasitol. 2005 ;143(1):121-4.
. Leishmania inactivation in human pheresis platelets by a psoralen (amotosalen HCl) and long-wavelength ultraviolet irradiation. Transfusion. 2005 ;45(9):1459-63.
. Protein farnesyl transferase inhibitors for the treatment of malaria and African trypanosomiasis. Curr Opin Investig Drugs. 2005 ;6(8):791-7.
. The protein farnesyltransferase inhibitor Tipifarnib as a new lead for the development of drugs against Chagas disease. J Med Chem. 2005 ;48(17):5415-8.
. Protein farnesyltransferase inhibitors exhibit potent antimalarial activity. J Med Chem. 2005 ;48(11):3704-13.
Structurally simple farnesyltransferase inhibitors arrest the growth of malaria parasites. Angew Chem Int Ed Engl. 2005 ;44(31):4903-6.
Upregulation of sterol C14-demethylase expression in Trypanosoma cruzi treated with sterol biosynthesis inhibitors. Mol Biochem Parasitol. 2005 ;144(1):68-75.
. Confirmation of Chagas' cardiomyopathy following heart transplantation. Heart Vessels. 2006 ;21(5):325-7.
. Crystal structure of glyceraldehyde-3-phosphate dehydrogenase from Plasmodium falciparum at 2.25 A resolution reveals intriguing extra electron density in the active site. Proteins. 2006 ;62(3):570-7.
Heterologous expression of proteins from Plasmodium falciparum: results from 1000 genes. Mol Biochem Parasitol. 2006 ;148(2):144-60.
Structurally simple, potent, Plasmodium selective farnesyltransferase inhibitors that arrest the growth of malaria parasites. J Med Chem. 2006 ;49(19):5710-27.
Structure of ribose 5-phosphate isomerase from Plasmodium falciparum. Acta Crystallogr Sect F Struct Biol Cryst Commun. 2006 ;62(Pt 5):427-31.
Structure of the conserved hypothetical protein MAL13P1.257 from Plasmodium falciparum. Acta Crystallogr Sect F Struct Biol Cryst Commun. 2006 ;62(Pt 3):180-5.
Thematic review series: lipid posttranslational modifications. Fighting parasitic disease by blocking protein farnesylation. J Lipid Res. 2006 ;47(2):233-40.
. Using fragment cocktail crystallography to assist inhibitor design of Trypanosoma brucei nucleoside 2-deoxyribosyltransferase. J Med Chem. 2006 ;49(20):5939-46.